Information Provided By: 
Fly News Breaks for March 8, 2019
ENDP
Mar 8, 2019 | 07:58 EDT
Canaccord analyst Dewey Steadman noted Endo shares have been under pressure due to concerns over the sustainability of the company's ex-injectables generics business and from competitors' news on the opioid litigation front. The analyst is looking for several upcoming catalysts for the company this year and continued execution on the company's key franchises, which he believes will lead to a second half of the year impact. Steadman reiterated his Buy rating and lowered his price target to $17 from $20 on Endo shares.
News For ENDP From the Last 2 Days
There are no results for your query ENDP
